The activity, safety, pharmacokinetic and pharmacodynamics data provided here thus demonstrate the superiority of CD123-NKCEs over comparator cytotoxic antibodies in terms of antitumor activity, and their favorable safety profiles relative to T cell therapies for the treatment of AML. The gene discussed is IL3RA; the disease is acute myeloid leukemia.